LGALS1 and cancer: In an extension of this work, benzimidazole-1,2,3-triazole hybrid compounds were synthesized as galectin-1 targeted agents based on compound 179 and were evaluated for their activity against NCI-H460, A549, MDA-MB-231, and MCF-7 cancer cell lines [163].